Doxorubicin Hydrochloride

Generic Name: doxorubicin hydrochloride

Over-the-Counter (OTC)

Brand Names:

Doxorubicin Hydrochloride Liposome

Doxorubicin Hydrochloride is a sterile liposomal dispersion containing doxorubicin hydrochloride encapsulated in pegylated liposomes for intravenous use in cancer treatment.

Overview

Doxorubicin Hydrochloride is a sterile liposomal dispersion containing doxorubicin hydrochloride encapsulated in pegylated liposomes for intravenous use in cancer treatment.

Uses

Treatment of ovarian cancer after platinum failure, AIDS-related Kaposi's sarcoma after prior chemotherapy failure or intolerance, and multiple myeloma combined with bortezomib.

Dosage

Ovarian cancer: 50 mg/m2 every 4 weeks. AIDS-KS: 20 mg/m2 every 3 weeks. Multiple myeloma: 30 mg/m2 on day 4 of cycles.

Side Effects

Most common adverse reactions (more than 20%) are asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea.

Interactions

No formal drug interaction studies have been conducted.

Warnings

BOXED WARNING: Cardiomyopathy risk of 11% at cumulative doses 450-550 mg/m2. Infusion-related reactions occurring in 11% of patients. Includes cardiomyopathy assessment, infusion reactions, hand-foot syndrome, secondary oral neoplasms, embryo-fetal toxicity. Contraindicated in severe hypersensitivity reactions and anaphylaxis to doxorubicin.

Frequently Asked Questions

What is Doxorubicin Hydrochloride used for?

Treatment of ovarian cancer after platinum failure, AIDS-related Kaposi's sarcoma after prior chemotherapy failure or intolerance, and multiple myeloma combined with bortezomib.

What are the side effects of Doxorubicin Hydrochloride?

Most common adverse reactions (more than 20%) are asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea.

What are the important warnings for Doxorubicin Hydrochloride?

BOXED WARNING: Cardiomyopathy risk of 11% at cumulative doses 450-550 mg/m2. Infusion-related reactions occurring in 11% of patients. Includes cardiomyopathy assessment, infusion reactions, hand-foot syndrome, secondary oral neoplasms, embryo-fetal toxicity. Contraindicated in severe hypersensitivity reactions and anaphylaxis to doxorubicin.

Related Medications

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.